CA2494636A1 - Organic compounds as agents for the treatment of aldosterone mediated conditions - Google Patents

Organic compounds as agents for the treatment of aldosterone mediated conditions Download PDF

Info

Publication number
CA2494636A1
CA2494636A1 CA002494636A CA2494636A CA2494636A1 CA 2494636 A1 CA2494636 A1 CA 2494636A1 CA 002494636 A CA002494636 A CA 002494636A CA 2494636 A CA2494636 A CA 2494636A CA 2494636 A1 CA2494636 A1 CA 2494636A1
Authority
CA
Canada
Prior art keywords
imidazo
pyrazin
phenyl
dihydro
bromo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002494636A
Other languages
English (en)
French (fr)
Inventor
Jeffrey Mckenna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2494636A1 publication Critical patent/CA2494636A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002494636A 2002-08-07 2003-08-06 Organic compounds as agents for the treatment of aldosterone mediated conditions Abandoned CA2494636A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40169302P 2002-08-07 2002-08-07
US60/401,693 2002-08-07
PCT/EP2003/008720 WO2004014914A1 (en) 2002-08-07 2003-08-06 Organic compounds as agents for the treatment of aldosterone mediated conditions

Publications (1)

Publication Number Publication Date
CA2494636A1 true CA2494636A1 (en) 2004-02-19

Family

ID=31715720

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002494636A Abandoned CA2494636A1 (en) 2002-08-07 2003-08-06 Organic compounds as agents for the treatment of aldosterone mediated conditions

Country Status (14)

Country Link
US (1) US7732603B2 (cg-RX-API-DMAC7.html)
EP (1) EP1537114B8 (cg-RX-API-DMAC7.html)
JP (1) JP4533139B2 (cg-RX-API-DMAC7.html)
CN (1) CN100404535C (cg-RX-API-DMAC7.html)
AT (1) ATE335744T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003253387A1 (cg-RX-API-DMAC7.html)
BR (1) BR0313293A (cg-RX-API-DMAC7.html)
CA (1) CA2494636A1 (cg-RX-API-DMAC7.html)
CY (1) CY1106217T1 (cg-RX-API-DMAC7.html)
DE (1) DE60307483T2 (cg-RX-API-DMAC7.html)
DK (1) DK1537114T3 (cg-RX-API-DMAC7.html)
ES (1) ES2270143T3 (cg-RX-API-DMAC7.html)
PT (1) PT1537114E (cg-RX-API-DMAC7.html)
WO (1) WO2004014914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612088B2 (en) * 2004-05-28 2009-11-03 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
AR049711A1 (es) * 2004-07-09 2006-08-30 Speedel Experimenta Ag Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
TW200716636A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716634A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW200813071A (en) * 2006-04-12 2008-03-16 Speedel Experimenta Ag Spiro-imidazo compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
WO2007139992A2 (en) * 2006-05-26 2007-12-06 Novartis Ag ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
WO2008027284A1 (en) * 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
AU2007337659A1 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
US8859538B2 (en) * 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
KR20110036069A (ko) * 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-a]피라진 화합물
CA2763565A1 (en) 2009-05-28 2010-12-02 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
PL2435409T3 (pl) 2009-05-28 2015-01-30 Novartis Ag Podstawione pochodne aminopropionowe jako inhibitory neprylizyny
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
CA2793313C (en) 2010-04-02 2018-01-23 Euroscreen Sa Nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
CA2849751C (en) 2011-10-03 2019-06-11 Euroscreen Sa Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
SG11201506018PA (en) 2013-02-14 2015-08-28 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EP3024845A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic polypeptides for the treatment of heart failure
JP6469214B2 (ja) 2014-09-25 2019-02-13 オゲダ エス.エー. N−アシル−(3−置換)−(8−置換)−5,6−ジヒドロ−[1,2,4]トリアゾロ[4,3−a]ピラジンの新規キラル合成
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
CN114702495A (zh) 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CA3095367A1 (en) 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) * 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
WO2020110008A1 (en) 2018-11-27 2020-06-04 Novartis Ag Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
JP7657151B2 (ja) 2018-11-27 2025-04-04 ノバルティス アーゲー 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド
JP7777131B2 (ja) 2020-10-02 2025-11-27 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
KR20230080441A (ko) 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
IL324432A (en) 2023-05-24 2026-01-01 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder
CN121045094A (zh) * 2025-04-17 2025-12-02 成都地奥制药集团有限公司 氘代的1,2,4-三嗪化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3582315A (en) * 1968-03-22 1971-06-01 Lilly Co Eli Methods and compositions for inhibiting plant growth
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
DE4237656A1 (de) * 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
JPH07101959A (ja) * 1993-09-30 1995-04-18 Sankyo Co Ltd 1−メチルカルバペネム誘導体
DE4341453A1 (de) * 1993-12-06 1995-06-08 Merck Patent Gmbh Imidazopyridine
AU6015796A (en) * 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
US20050014939A1 (en) * 1999-08-31 2005-01-20 Neurogen Corporation Fused pyrrolecarboxamides: GABA brain receptor ligands
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
DK1537114T3 (da) 2006-11-13
EP1537114B1 (en) 2006-08-09
JP4533139B2 (ja) 2010-09-01
CN1688583A (zh) 2005-10-26
CY1106217T1 (el) 2011-06-08
ES2270143T3 (es) 2007-04-01
EP1537114A1 (en) 2005-06-08
JP2006505520A (ja) 2006-02-16
DE60307483T2 (de) 2007-07-05
ATE335744T1 (de) 2006-09-15
PT1537114E (pt) 2006-12-29
WO2004014914A1 (en) 2004-02-19
HK1080290A1 (en) 2006-04-21
CN100404535C (zh) 2008-07-23
DE60307483D1 (de) 2006-09-21
BR0313293A (pt) 2005-06-14
US7732603B2 (en) 2010-06-08
AU2003253387A1 (en) 2004-02-25
EP1537114B8 (en) 2007-10-03
US20060166973A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
EP1537114B1 (en) Organic compounds as agents for the treatment of aldosterone mediated conditions
EP1565463B1 (en) Imidazo[1,5a] pyridine derivatives and methods for treating aldosterone mediated diseases
CN109071552B (zh) 细胞周期蛋白依赖性激酶4/6(cdk4/6)通过cdk4/6抑制剂与e3连接酶配体的缀合的降解及使用方法
EP3541390B1 (en) Pyrrolopyrimidines as cftr potentiators
AU2017382029B2 (en) Bicyclic dihydropyrimidine-carboxamide derivatives as Rho-kinase inhibitors
JP4846665B2 (ja) ピラゾロ[1,5−a]ピリミジン化合物
US20170020879A1 (en) Pyrazolopyridyl compounds as aldosterone synthase inhibitors
WO2007117180A1 (fr) Bibliothèques combinatoire et focalisée d'azahétérocycles, composition pharmaceutique et procédés de leur fabrication
KR20090015092A (ko) 폴리(adp-리보스)폴리머라제(parp)의 억제제로서의 피리디논 및 피리다지논 유도체
JP2006505520A5 (cg-RX-API-DMAC7.html)
JP2010540424A (ja) チエノピリミジン化合物類および組成物
CA2671525A1 (en) Indolylmaleimide derivatives
CN102177161A (zh) Jnk的嘧啶基吡啶酮抑制剂
CN108602829A (zh) Cxcr4受体拮抗剂
US20100305143A1 (en) Pyrrolopyrimidine compounds
KR100750028B1 (ko) 치료에 유용한 트리아졸 화합물
JP2002513382A (ja) アゾロトリアジン類およびアゾロピリミジン類
HK1080290B (en) Organic compounds as agents for the treatment of aldosterone mediated conditions
RU2778478C2 (ru) Бициклические производные дигидропиримидинкарбоксамида в качестве ингибиторов rho-киназы
HK1081540B (en) Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases
HK40010452B (en) Bicyclic dihydropyrimidine-carboxamide derivatives as rho-kinase inhibitors
HK40014108A (en) Pyrrolopyrimidines as cftr potentiators
HK40014108B (en) Pyrrolopyrimidines as cftr potentiators

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued